About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 7280 record(s)
Req # A-2023-001074
All external documents, information and documents held by Health Canada with respect to discussions of whether and how chemically synthesized drug products can use a biologic drug as the Canadian Reference Product, from January 2017 to November 14,…Organization: Health Canada
June 2024
Req # A-2023-001217
The Section 1.0.7 “Note to the Reviewer” (Module 1.0.7) from the generic manufacturer of the Second Liraglutide Abbreviated New Drug Submission (ANDS).Organization: Health Canada
June 2024
Req # A-2023-001219
In respect of the second, newest Abbreviated New Drug Submission (ANDS) for liraglutide provide copies of all correspondence or other records relating to any pre-submission or pre-application meeting(s) requested by the sponsor.Organization: Health Canada
June 2024
Req # A-2023-001220
Correspondence relating to any abbreviated new drug submission (ANDS) filed since July 1, 2023 where the medicinal ingredient is liraglutide alone and the indication includes the treatment of adults with type 2 diabetes.Organization: Health Canada
June 2024
Req # A-2023-001258
All "red notices" Health Canada posted on internal systems in 2023, warning or alerting employees of allegations of misconduct or noncompliance by a private company, organization or individual.Organization: Health Canada
June 2024
Req # A-2023-001261
All "red notices" Health Canada posted on internal systems in 2020, 2021 and 2022 warning or alerting employees of allegations of misconduct or noncompliance by a private company, organization or individual.Organization: Health Canada
June 2024
Req # A-2023-001271
New Drug Submission (NDS) for avapritinib filed by Blueprint Medicines Corporation was accepted into review by Health Canada in or around November 2023. Provide the Product Information Template: Regulatory Enrollment Process (the equivalent of…Organization: Health Canada
June 2024
Req # A-2023-001273
Correspondence relating to any New Drug Submission (NDS) filed since July 1, 2023, where the medicinal ingredient is avaprinitib alone and the product’s indications are included.Organization: Health Canada
June 2024
Req # A-2023-001277
New Drug Submission (NDS) for avapritinib filed by Blueprint Medicines Corporation was accepted into review by Health Canada in or around November 2023. Provide a non-annotated copy of the most recent Certified Product Information Document (CPID)…Organization: Health Canada
June 2024
Req # A-2023-001321
The Abbreviated New Drug Submission (ANDS) cover letter of the company (sponsor) who submitted the Mesalazine ANDS.Organization: Health Canada
June 2024